MAML2 and brain neoplasm: In vivo, mutation of the TEAD binding site of YAP in YAP::MAML2, YAP::MAMLD1, YAP::FAM118B, YAP::SS18, and YAP::TFE3 significantly reduced the oncogenic potential of these protein fusions to initiate brain tumors in mice (Pajtler et al. 2019; Szulzewsky et al. 2020, 2022).